Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

This study has been completed.

Study NCT00003694 Information provided by Cancer and Leukemia Group B

First Received: November 1, 1999 Last Updated: April 1, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	April 2009
Primary Completion Date:	August 2003 (Final data collection date for primary outcome measure)

Publications:

Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA; for the Cancer and Leukemia Group B. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2008 Aug 1; [Epub ahead of print]

Stone R, Yu D, Stock W, et al.: A phase II trial of homoharringtonine (HHT) in combination with low-dose cytarabine (lodac) via continuous intravenous infusion (CIVI) for newly diagnosed patients (pts) with chronic myeloid leukemia (CML): CALGB 19804. [Abstract] Blood 100 (11 Pt 1): A-3101, 2002.